Why Abzena?
Trust our focused approach.
Welcome to Abzena. The leading complex biologics and bioconjugates CDMO +CRO.
Trust our focused approach.
Meet our experienced team.
Partnering for success.
Quality is culture.
20+ years of biologics expertise.
State-of-the-art, global facilities.
Earning customer trust.
Recognition of our success.
Meet our scientific experts.
End-to-end biologics CDMO + CRO services for modalities inc. mAbs, ADCs, AOCs, RDCs, fusion proteins, bispecifics & more underpinned by robust analytical capabilities across all phases of development.
High Affinity, Desired Biological Activity, Hybridoma Sequencing...
Antibody Design, Protein Engineering, Antibody Humanization, Deimmunization...
Early De-Risking & Developability, Antibody Development...
Analytical Method Development, Fc Binding & Functional Assays...
EpiScreen® 2.0, Immunogenicity Risk Assessments, T Cell Assay...
GMP-Ready, Fully Portable, No Abzena Exit Fees, No Royalties, Single Milestone Payment at IND*
Monoclonal Antibodies, Proteins, Antibody-Drug Conjugates...
Upstream & Downstream, Process Transfer, Scale Up, Characterization & Validation, CLD > Patient...
Clinical Thru Commercial, Tech Transfer, Scale Up, Quality...
Specialized bioconjugation services across ADCs, AOCs, RDCs, linker payload, chemistry & polymers underpinned by leading analytical capabilities.
Payload Design & Synthesis, Analytical Methods, HPAPI...
ADC, AOC, RDC Design & Discovery...
ADC, AOC, RDC Development, De-Risking & Developability...
Complex & Analytical Chemistry, Polymer Conjugate Formulation...
Analytical Method Development, Bioconjugate Characterization...
Seamless Transfer, Quality Commitment, Regulatory Compliance, ADC Tech Transfer
ADC Formulation, Customized, Stable Liquid & Lyophilized...
Process Transfer, Scale Up, Characterization & Validation, Stability...
ADC Manufacturing, Clinical Thru Commercial, Tech Transfer...
Technologies & solutions for shortening timelines & de-risking development across all stages. Your ideas, our solutions.
Discover AbZelectPRO™ + New CHOSOURCE™ GS Knockout Cell Line Technology Platforms
Discover EpiScreen® 2.0
Starting smart, finishing fast.
Discover LabZient™
Discover Composite Human Antibody™
Discover ThioBridge®
Discover Composite Proteins™
Sharing our scientific innovation and unique knowledge.
Unique insights into how we partner with our customers.
Offering an overview of our services and expertise.
Published scientific articles reviewed by our peers.
Looking for inspiration? Our whitepapers can help.
Watch our experts share their knowledge on-demand.
Access to our latest scientific featured articles.
At the recent Biologics US event in San Diego, our Sr. Director of Bioassays, Dr Erika Kovacs presented a poster entitled, “Rapid Developability Assessments to Assist Lead Candidate Selection.”
The poster highlights our robust developability platform, which integrates in silico approaches with characterization and stability studies to determine the selection of the best candidate to progress.
Using a panel of 7 mAb sequences that were expressed in ExpiCHO by transient transfection and characterized by SDS-PAGE and analytical SEC before assessment, the poster details the different computational tools employed to identify sequence liabilities, and immunogenicity risks, while advanced biophysical techniques evaluated manufacturability and stability.
Poster authors include: Robert Cunningham, Judit Csapo, Emily Mallet, Marta Bussee, Marina Leal, Patrick Lynch, Aaron Hearn, Erika Kovacs, Williams McDowell, Rob Holgate